MCID: FXF002
MIFTS: 37

Fox-Fordyce Disease

Categories: Rare diseases, Skin diseases

Aliases & Classifications for Fox-Fordyce Disease

MalaCards integrated aliases for Fox-Fordyce Disease:

Name: Fox-Fordyce Disease 12 50 42 14
Fox Fordyce Disease 12 69
Fox-Fordyce Syndrome 50
Miliaria, Apocrine 50
Apocrine Miliaria 50

Classifications:



External Ids:

Disease Ontology 12 DOID:1381
ICD10 33 L75.2
ICD9CM 35 705.82
MeSH 42 D005588
NCIt 47 C84716
SNOMED-CT 64 254682006 65038009
UMLS 69 C0016632

Summaries for Fox-Fordyce Disease

NIH Rare Diseases : 50 fox-fordyce disease is a chronic skin disease most common in women aged 13-35 years. it is characterized by the development of intense itching in the underarm area, the pubic area, and around the nipple of the breast as a result of perspiration which becomes trapped in the sweat gland and surrounding areas. the cause is unknown, but heat, humidity, and stress may play a role. treatment may include the use of retinoids, antibiotics, and immunosuppressants. last updated: 8/3/2016

MalaCards based summary : Fox-Fordyce Disease, also known as fox fordyce disease, is related to pericoronitis and xanthomatosis. An important gene associated with Fox-Fordyce Disease is OSMR (Oncostatin M Receptor), and among its related pathways/superpathways is Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Dopamine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and prostate.

Wikipedia : 72 Fox–Fordyce disease, or apocrine miliaria, is a chronic blockage of the sweat gland ducts with a... more...

Related Diseases for Fox-Fordyce Disease

Diseases related to Fox-Fordyce Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 49)
id Related Disease Score Top Affiliating Genes
1 pericoronitis 10.3 KIT OSMR
2 xanthomatosis 10.3
3 liver inflammatory pseudotumor 10.2 CEACAM5 KIT
4 superficial basal cell carcinoma 10.2 CEACAM5 KIT
5 gastric papillary adenocarcinoma 10.2 CEACAM5 KIT
6 sphenoid sinus squamous cell carcinoma 10.2 CEACAM5 KIT
7 webster deming syndrome 10.2 CEACAM5 KIT
8 urethral villous adenoma 10.1 CEACAM5 KIT
9 trachea adenoid cystic carcinoma 10.1 CEACAM5 PIP
10 vulvar angiokeratoma 10.1 CEACAM5 PIP
11 vulva squamous cell carcinoma 10.1 CEACAM5 PIP
12 anterolateral myocardial infarction 10.1 CEACAM5 KIT
13 miliaria 10.1
14 hidradenitis 10.1
15 pineal region meningioma 10.1 CEACAM5 PIP
16 parietal lobe neoplasm 10.1 CEACAM5 PIP
17 bronchiolo-alveolar adenocarcinoma 10.1 CEACAM5 PIP
18 myotonia congenita 10.1 CEACAM5 PIP
19 spiradenoma 10.0 KIT PIP
20 necrobiosis lipoidica 10.0 CD68 OSMR
21 gastrointestinal neuroendocrine tumor 10.0 CEACAM5 KIT
22 medullary thyroid carcinoma, familial 10.0 CEACAM5 OSMR
23 vestibular gland benign neoplasm 10.0 CEACAM5 KIT
24 turner syndrome 10.0
25 syringoma 10.0
26 hidradenitis suppurativa 10.0
27 avian influenza 10.0 CEACAM5 PIP
28 paratesticular lipoma 9.9 CD68 KIT
29 filamentary keratitis 9.9 CD68 KIT
30 superior vena cava leiomyosarcoma 9.9 CD68 CEACAM5
31 fallopian tube squamous cell carcinoma 9.9 CD68 KIT
32 retinal disease 9.9 KIT PIP
33 queensland tick typhus 9.9 CD68 MRAP
34 pigmented villonodular synovitis 9.9 CD68 CEACAM5
35 brain stem infarction 9.9 CD68 KIT
36 cholelithiasis 9.8 CD68 CEACAM5
37 tricuspid valve prolapse 9.8 CD68 MRAP
38 gallbladder cancer 9.8 CEACAM5 KIT
39 leprosy 6 9.8 CEACAM5 KIT
40 partial of retinal vein occlusion 9.8 CD68 CEACAM5
41 mucin-rich endometrial endometrioid adenocarcinoma 9.8 CD68 CEACAM5
42 transient neonatal thrombocytopenia 9.8 CD68 CEACAM5
43 bone marrow cancer 9.7 CD68 KIT
44 brown-vialetto-van laere syndrome 9.7 CEACAM5 KIT
45 gestational choriocarcinoma 9.6 CD68 KIT
46 frontotemporal dementia and/or amyotrophic lateral sclerosis 4 9.6 CEACAM5 OSMR
47 heavy chain disease 9.6 CEACAM5 KIT PIP
48 squamous blepharitis 9.3 CD68 CEACAM5 PIP
49 hypoglossal nerve disease 7.9 CD68 CEACAM5 KIT MRAP OSMR PIP

Graphical network of the top 20 diseases related to Fox-Fordyce Disease:



Diseases related to Fox-Fordyce Disease

Symptoms & Phenotypes for Fox-Fordyce Disease

Drugs & Therapeutics for Fox-Fordyce Disease

Drugs for Fox-Fordyce Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 721)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
2
Memantine Approved, Investigational Phase 4,Phase 3 19982-08-2 4054
3
Treprostinil Approved, Investigational Phase 4 81846-19-7 54786 6918140
4
Acetylcholine Approved Phase 4 51-84-3 187
5
Epoprostenol Approved Phase 4 61849-14-7, 35121-78-9 5280427 5282411
6
Iloprost Approved, Investigational Phase 4,Phase 1,Phase 2 78919-13-8 6443959
7
Tadalafil Approved, Investigational Phase 4,Phase 3 171596-29-5 110635
8
Nicotine Approved Phase 4,Phase 2 54-11-5 942 89594
9
Pramipexole Approved, Investigational Phase 4,Phase 2 104632-26-0 59868 119570
10
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
11
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
12
Zoledronic acid Approved Phase 4,Phase 3 118072-93-8 68740
13
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
14
Insulin Glargine Approved Phase 4 160337-95-1
15
Zinc Approved Phase 4,Phase 3 7440-66-6 32051 23994
16
Ethanol Approved Phase 4,Phase 2,Phase 1 64-17-5 702
17
Amantadine Approved Phase 4,Phase 2 768-94-5 2130
18
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
19
Ropinirole Approved, Investigational Phase 4,Phase 2 91374-20-8, 91374-21-9 5095 497540
20
Methylphenidate Approved, Investigational Phase 4,Phase 3 113-45-1 4158
21
Phentolamine Approved Phase 4 50-60-2 5775
22
Fesoterodine Approved Phase 4 286930-02-7, 286930-03-8 6918558
23
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
24
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
25
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
26
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 1 134678-17-4 60825
27
Ibuprofen Approved Phase 4 15687-27-1 3672
28
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
30
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
31
Caffeine Approved, Nutraceutical Phase 4 58-08-2 2519
32
Lactitol Investigational Phase 4 585-86-4 3871
33 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2
36 Excitatory Amino Acids Phase 4,Phase 3,Phase 2
37 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
40 abobotulinumtoxinA Phase 4
41 Botulinum Toxins Phase 4
42 Botulinum Toxins, Type A Phase 4
43 Cholinergic Agents Phase 4,Phase 3,Phase 2,Early Phase 1
44 onabotulinumtoxinA Phase 4
45 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3
46 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2
47 Tezosentan Phase 4
48 Vardenafil Dihydrochloride Phase 4
49 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1372)

id Name Status NCT ID Phase Drugs
1 Memantine for Agitation in Dementia Unknown status NCT00371059 Phase 4 Memantine;Placebo
2 Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain Unknown status NCT01615627 Phase 4 HypotonicTreprostinil Solution;Eutonic Treprostinil Solution
3 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4 Botulinum Toxin
4 Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids. Unknown status NCT00705588 Phase 4 Tadalafil;Vardenafil
5 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
6 Merck IISP Stewardship Grant for Antibiotic Best Practices Completed NCT01573195 Phase 4
7 The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes Completed NCT00353834 Phase 4 Exenatide;Glargine Insulin
8 Effects of White Wine vs. Tea Intake During and an Alcoholic Digestive Following a High Fat, High Calorie Cheese Fondue Meal on Gastric Emptying and Abdominal Symptoms in Healthy Volunteers Completed NCT00943696 Phase 4
9 Validation of Dyskinesia Rating Scales Completed NCT01071395 Phase 4 Amantadine;Placebo
10 Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
11 Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease Completed NCT00526630 Phase 4 Methylphenidate (MPD);Placebo
12 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
13 Spy II Clinical Registry Completed NCT00751998 Phase 4
14 A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE) Completed NCT00096928 Phase 4
15 A Multiple Myeloma Trial in Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
16 A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine. Completed NCT01302054 Phase 4 Fesoterodine 8 mg;Placebo
17 Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging Completed NCT01221272 Phase 4 Ranolazine;Placebo to match ranolazine
18 A Study to Determine if Caffeine Accelerates Emergence From Anesthesia Recruiting NCT02567968 Phase 4 Caffeine;Placebo Control
19 Safety and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients Recruiting NCT02583399 Phase 4 Ibuprofen
20 Kunxian for the Treatment of Rheumatoid Arthritis Recruiting NCT02764515 Phase 4 Kunxian Capsule;Methotrexate
21 Fentanyl Patch Pharmacokinetics in Healthy Adults Recruiting NCT02531971 Phase 4 Intravenous fentanyl citrate;Duragesic®;Mylan generic fentanyl
22 Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF) Recruiting NCT02827500 Phase 4 ivabradine
23 Atrial Fibrillation Progression Trial Recruiting NCT01570361 Phase 4 Drug Treatment
24 Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator Active, not recruiting NCT01742299 Phase 4 STI571
25 Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection Not yet recruiting NCT03205566 Phase 4 Raltegravir 400Mg Tab;Lamivudine 150Mg Tablet
26 An Adequate Cost Effective Follow Up Protocol For Bone & Soft Tissue Sarcomas - A Prospective Randomized Trial Unknown status NCT00384735 Phase 3
27 Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy Unknown status NCT00516464 Phase 3 Lucentis (ranibizumab)
28 Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients Unknown status NCT01333358 Phase 3 Alemtuzumab
29 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
30 Treating H. Pylori in Parkinson's Patients With Motor Fluctuations Unknown status NCT00664209 Phase 3 clartihromycin, amoxicillin, and omeprazole;placebo
31 Boost Use in Breast Conservation Radiotherapy Unknown status NCT00138814 Phase 3
32 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
33 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Unknown status NCT00003389 Phase 3 Doxorubicin;Bleomycin;Vinblastine;Dacarbazine;Vincristine;Mechlorethamine;Etoposide;Prednisone;Cyclophosphamide
34 Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Unknown status NCT00117572 Phase 3 docetaxel;cisplatin;hydroxyurea;fluorouracil
35 Vaccine Therapy for Patients With Stage III Melanoma Unknown status NCT00052130 Phase 3
36 A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis Unknown status NCT00628680 Phase 3 Heparin
37 Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization Unknown status NCT00438867 Phase 3
38 Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation Unknown status NCT00691470 Phase 2, Phase 3 ATI-5923;Coumadin (warfarin)
39 Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer Unknown status NCT00365105 Phase 3 zoledronic acid;Sm-153
40 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
41 Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate Cancer Completed NCT00062309 Phase 3
42 Computer-Based Survey and Communication Aid in Improving Physician-Patient Communication and Treatment Decision Making in Patients With Metastatic Cancer Completed NCT00244868 Phase 3
43 Educational Intervention With or Without Telephone Counseling in Increasing Colorectal Cancer Screening Compliance in Brothers and Sisters of Patients With Colorectal Cancer Completed NCT00352638 Phase 3
44 Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer Completed NCT00003313 Phase 3 amifostine trihydrate;carboplatin;paclitaxel
45 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
46 The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction Completed NCT00143507 Phase 3 Ivabradine;Placebo
47 Study of APD421 as PONV Treatment (Prior Prophylaxis) Completed NCT02646566 Phase 3 APD421;Placebo
48 Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer Completed NCT00767286 Phase 3 flutamide;goserelin acetate
49 S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer Completed NCT00004011 Phase 3 carboplatin;paclitaxel
50 Long-term Effect of Low Frequency Stimulation on Aspiration and Freezing of Gait in PD With STN DBS Completed NCT02549859 Phase 2, Phase 3

Search NIH Clinical Center for Fox-Fordyce Disease

Cochrane evidence based reviews: fox-fordyce disease

Genetic Tests for Fox-Fordyce Disease

Anatomical Context for Fox-Fordyce Disease

MalaCards organs/tissues related to Fox-Fordyce Disease:

39
Lung, Breast, Prostate, Bone, Kidney, Liver, Skin

Publications for Fox-Fordyce Disease

Articles related to Fox-Fordyce Disease:

(show top 50) (show all 78)
id Title Authors Year
1
A novel modality using microwave technology for the treatment of Fox-Fordyce disease (FFD). ( 27051811 )
2016
2
In vivo features of Fox-Fordyce disease in high-definition optical coherence tomography. ( 26972218 )
2016
3
Fox-Fordyce disease of the vulva. ( 27190415 )
2016
4
Effective treatment of Fox-Fordyce disease with pulsed dye laser. ( 27623097 )
2016
5
Successful treatment of areolar Fox-Fordyce disease with surgical excision and 1550-nm fractionated erbium glass laser. ( 27072751 )
2016
6
Fox-Fordyce Disease: An under-diagnosed adverse event of laser hair removal? ( 27135989 )
2016
7
Fox-Fordyce Disease. ( 26909204 )
2016
8
In vivo features of Fox-Fordyce disease in high-definition optical coherence tomography. ( 26713641 )
2016
9
A female case of Fox-Fordyce disease. ( 27226051 )
2016
10
Lesions in the axilla after hair removal using intense pulsed light. Fox-Fordyce disease. ( 24838226 )
2015
11
Clinical Effects of Topical Tacrolimus on Fox-Fordyce Disease. ( 26171257 )
2015
12
Axillary syringomas mimicking Fox-Fordyce disease. ( 26500884 )
2015
13
Successful treatmeant of refractory pruritic Fox-Fordyce disease with botulinum Toxin Type A. ( 26385128 )
2015
14
Fox-Fordyce disease: a report of 2 cases responding to topical clindamycin. ( 25566917 )
2015
15
Fox-Fordyce disease treatment with fractional CO2 laser. ( 24261728 )
2013
16
Fox Fordyce disease as a secondary effect of laser hair removal. ( 24131099 )
2013
17
Fox-Fordyce disease with an atypical clinical presentation. ( 23260875 )
2013
18
Clinical effects of topical pimecrolimus in a patient with Fox-Fordyce disease. ( 22571582 )
2012
19
Fox-Fordyce disease: response to adapalene 0.1%. ( 22570049 )
2012
20
Anti-human milk fat globulin staining of perifollicular xanthomatosis inA Fox-Fordyce disease. ( 23181442 )
2012
21
Fox-Fordyce disease. ( 23286818 )
2012
22
Histopathology attributes of Fox-Fordyce disease. ( 23067079 )
2012
23
Fox-Fordyce disease in monozygotic female twins. ( 21679831 )
2011
24
Fox-Fordyce disease following axillary laser hair removal. ( 21576577 )
2011
25
Fox-Fordyce Disease (Apocrine Miliaria). ( 21751451 )
2011
26
Fox-Fordyce disease exacerbated by hyperhidrosis. ( 20537067 )
2010
27
Fox-Fordyce disease in daughter and father. ( 19060475 )
2009
28
Clinicopathological study of Fox-Fordyce disease. ( 19712275 )
2009
29
Dilation of apocrine glands. A forgotten but helpful histopathological clue to the diagnosis of axillary Fox-Fordyce disease. ( 19461248 )
2009
30
Perifollicular xanthomatosis as the hallmark of axillary Fox-Fordyce disease: an evaluation of histopathologic features of 7 cases. ( 18711075 )
2008
31
Pruritic axillary papules. Fox-Fordyce disease. ( 18619083 )
2008
32
Pimecrolimus is effective in Fox-Fordyce disease. ( 16961542 )
2006
33
Fox fordyce disease in a prepubertal girl. ( 15660912 )
2005
34
Axillary perifollicular xanthomatosis resembling Fox-Fordyce disease. ( 15527440 )
2004
35
Patterns histopathologic of Fox-Fordyce disease. ( 15618931 )
2004
36
Axillary perifollicular xanthomatosis resembling Fox-Fordyce disease. ( 15068468 )
2004
37
Apoeccrine sweat duct obstruction as a cause for Fox-Fordyce disease. ( 12637930 )
2003
38
Fox-Fordyce disease. ( 12705772 )
2003
39
Fox-Fordyce disease. ( 12041809 )
2002
40
Axillary Fox-Fordyce disease treated with liposuction-assisted curettage. ( 11939804 )
2002
41
Fox-Fordyce disease: diagnosis with transverse histologic sections. ( 10607326 )
2000
42
Fox-Fordyce disease: two cases in patients with Turner syndrome. ( 10086869 )
1999
43
Fox-Fordyce disease in two prepubertal girls: histopathologic demonstration of eccrine sweat gland involvement. ( 8844748 )
1996
44
Fox-Fordyce disease treated with topical clindamycin solution. ( 7574824 )
1995
45
Fox-Fordyce disease in a male patient--response to oral retinoid treatment. ( 8313643 )
1994
46
Fox-Fordyce disease: successful treatment with topical clindamycin in alcoholic propylene glycol solution. ( 1498406 )
1992
47
Tretinoin treatment for Fox-Fordyce disease. ( 507877 )
1979
48
Fox-Fordyce disease. Control with tretinoin cream. ( 507892 )
1979
49
Fox-Fordyce disease. Self-assessment mini-program. ( 457328 )
1979
50
Hormonal levels in Fox-Fordyce disease. ( 1252362 )
1976

Variations for Fox-Fordyce Disease

Expression for Fox-Fordyce Disease

Search GEO for disease gene expression data for Fox-Fordyce Disease.

Pathways for Fox-Fordyce Disease

Pathways related to Fox-Fordyce Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.87 CD68 CEACAM5 KIT

GO Terms for Fox-Fordyce Disease

Sources for Fox-Fordyce Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....